Cascadian Therapeutics Announces 2018 Outlook and Recent Progress
04 janv. 2018 08h30 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for tucatinib, an...
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
02 janv. 2018 08h30 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it received a product-specific pediatric...
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index
13 déc. 2017 08h35 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage biopharmaceutical company, today announced that it has been selected for addition to the...
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
07 déc. 2017 16h05 HE
|
Cascadian Therapeutics, Inc.
SAN ANTONIO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of...
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results
08 nov. 2017 16h01 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended...
Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017
01 nov. 2017 09h19 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter financial...
Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November
24 oct. 2017 08h05 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Scott D. Myers, President and Chief Executive...
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer
27 sept. 2017 07h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA")...
Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
20 sept. 2017 09h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cantor...
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
11 sept. 2017 06h00 HE
|
Cascadian Therapeutics, Inc.
Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases Data from Nonclinical Models Support Evaluation of...